The Icahn School of Medicine at Mount Sinai announced today that it has signed a memorandum of understanding with the Chiba Institute of Technology (CIT) to collaborate on using artificial intelligence (AI) for cardiovascular disease research. The goal is to make clinical trials more efficient, lead to quicker advances in patient care, and bring possible new treatments to heart patients more quickly.
"Clinical cardiovascular diseases are areas of utmost priority and concern worldwide," said Deepak L. Bhatt, MD, MPH, FACC, FAHA, Director of Mount Sinai Heart and Dr. Valentin Fuster Professor of Cardiovascular Medicine at Icahn Mount Sinai. "Our partnership with the Chiba Institute of Technology presents an invaluable opportunity to harness the power of computational sciences, pushing the boundaries of what we can achieve. I firmly believe that our joint initiatives will contribute to advances in these fields, helping us create a healthier world."
The affiliation between the two institutions aims to enhance the understanding, prevention, and treatment of cardiovascular disease, and develop new strategies to combat this global health challenge.
Under this partnership, Mount Sinai and CIT will launch international clinical trials involving AI and interventional cardiology, cardiac electrophysiology, heart failure, cardiac imaging, and preventive cardiology. The research will also focus on reducing bias involving gender and race at the intersection of AI and cardiovascular research and aims to improve patient care and outcomes.
"This is a significant step in bridging technology and health care, demonstrating our shared commitment to using innovation for the betterment of human health. We look forward to collaborating with our colleagues at CIT to advance the frontier of medical science," explains Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System.
